Bitterman Chris T. 4

What Happened Chris T. Bitterman, Vice President of Sales & Marketing at Cumberland Pharmaceuticals (CPIX), was granted 3,000 shares on March 18, 2026. The award is reported as a derivative acquisition at $2.80 per share, giving a reported total value of $8,400. This was an equity grant/award (compensation-related), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-18; Form 4 filed: 2026-03-20 (filed within the typical two-business-day reporting window).
• Transaction type: A = Award/Grant (reported as a derivative acquisition).
• Shares and value: 3,000 shares at $2.80 each; total reported value $8,400.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes/plan details: None provided in the excerpt; no 10b5-1 plan, tax withholding, or cashless sale noted.
• Timeliness: Filing appears timely (not marked late).

Context An "A" (award/grant) derivative transaction usually reflects compensation (e.g., restricted stock, RSUs, or performance-based awards) rather than a market-driven purchase. Such grants are common as part of executive or employee compensation and do not, by themselves, indicate insider buying conviction or an immediate sale of shares.